206 related articles for article (PubMed ID: 8257832)
1. Role of natural killer cells in cancer.
Pross HF; Lotzová E
Nat Immun; 1993; 12(4-5):279-92. PubMed ID: 8257832
[TBL] [Abstract][Full Text] [Related]
2. Role of human circulating and tumor-infiltrating lymphocytes in cancer defense and treatment.
Lotzová E
Nat Immun Cell Growth Regul; 1990; 9(4):253-64. PubMed ID: 2215514
[TBL] [Abstract][Full Text] [Related]
3. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
4. Effects of systemic recombinant interleukin-2 on natural killer and lymphokine activated killer activity of human tumor infiltrating lymphocytes.
Anderson TM; Ibayashi Y; Tokuda Y; Colquhoun SD; Holmes EC; Golub SH
Cancer Res; 1988 Mar; 48(5):1180-3. PubMed ID: 3257716
[TBL] [Abstract][Full Text] [Related]
5. [Antitumor activity of human tumor infiltrating lymphocytes (TIL) and its comparison with peripheral blood lymphocytes (PBL)].
Xu ZY
Zhonghua Zhong Liu Za Zhi; 1990 Sep; 12(5):345-7. PubMed ID: 2177396
[TBL] [Abstract][Full Text] [Related]
6. Antileukemia activity of a natural killer cell line against human leukemias.
Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
[TBL] [Abstract][Full Text] [Related]
7. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
8. [The effect of sera of breast cancer patients on NK cell activity].
Konjević G; Spuzić I
Srp Arh Celok Lek; 1995; 123(9-10):227-31. PubMed ID: 17974436
[TBL] [Abstract][Full Text] [Related]
9. Design and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts.
Klingemann HG; Deal H; Reid D; Eaves CJ
Exp Hematol; 1993 Aug; 21(9):1263-70. PubMed ID: 8330650
[TBL] [Abstract][Full Text] [Related]
10. Human natural killer cells: a comprehensive review.
Sinkovics JG; Horvath JC
Int J Oncol; 2005 Jul; 27(1):5-47. PubMed ID: 15942642
[TBL] [Abstract][Full Text] [Related]
11. Interleukin (IL)-2 deficiency aggravates the defect of natural killer cell activity in AIDS patients.
Zerhouni B; Sanhadji K; Kehrli L; Livrozet JM; Touraine JL
Thymus; 1997; 24(3):147-56. PubMed ID: 9151380
[TBL] [Abstract][Full Text] [Related]
12. Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission.
Torelli GF; Guarini A; Maggio R; Alfieri C; Vitale A; Foà R
Haematologica; 2005 Jun; 90(6):785-92. PubMed ID: 15951291
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effects of interleukin-2 on natural killer activity in lung cancer patients.
Ito M; Suzuki H; Yamashita N; Sugiyama E; Maruyama M; Sato M; Iwata M; Yano S
Anticancer Res; 1984; 4(6):375-8. PubMed ID: 6097158
[TBL] [Abstract][Full Text] [Related]
14. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F
Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma.
Schleypen JS; Baur N; Kammerer R; Nelson PJ; Rohrmann K; Gröne EF; Hohenfellner M; Haferkamp A; Pohla H; Schendel DJ; Falk CS; Noessner E
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):718-25. PubMed ID: 16467081
[TBL] [Abstract][Full Text] [Related]
16. Dual effects of cytokines in regulation of MHC-unrestricted cell mediated cytotoxicity.
Reiter Z
Crit Rev Immunol; 1993; 13(1):1-34. PubMed ID: 8466640
[TBL] [Abstract][Full Text] [Related]
17. Defective natural cytotoxicity in patients with cancer: normal number of effector cells but decreased recycling capacity in patients with advanced disease.
Steinhauer EH; Doyle AT; Reed J; Kadish AS
J Immunol; 1982 Nov; 129(5):2255-9. PubMed ID: 7119445
[TBL] [Abstract][Full Text] [Related]
18. Cell therapy: achievements and perspectives.
Bordignon C; Carlo-Stella C; Colombo MP; De Vincentiis A; Lanata L; Lemoli RM; Locatelli F; Olivieri A; Rondelli D; Zanon P; Tura S
Haematologica; 1999 Dec; 84(12):1110-49. PubMed ID: 10586214
[TBL] [Abstract][Full Text] [Related]
19. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
20. Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo.
Whiteside TL; Sung MW; Nagashima S; Chikamatsu K; Okada K; Vujanovic NL
Clin Cancer Res; 1998 May; 4(5):1135-45. PubMed ID: 9607570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
